

WHAT IS CLAIMED:

1. ~~A binding agent that specifically binds human immunoglobulin-like transcript 3 (ILT3), which comprises:~~
 - (a) ~~a heavy chain variable region comprising a heavy chain variable region CDR1 comprising an amino acid sequence identical or substantially identical to GFTFSSYGMS (SEQ ID NO:27), a heavy chain variable region CDR2 comprising an amino acid sequence identical or substantially identical to TISGGGSYTNYPDSVKG (SEQ ID NO:28), and a heavy chain variable region CDR3 comprising an amino acid sequence identical or substantially identical to REWRMTLYAMDY (SEQ ID NO:29) or REWRYTLYAMDY (SEQ ID NO:105), and~~
 - (b) ~~a light chain variable region comprising a light chain variable region CDR1 comprising an amino acid sequence identical or substantially identical to RASESVDSYGNFSMH (SEQ ID NO:30) or RASESVESYGSSFMH (SEQ ID NO:106), a light chain variable region CDR2 comprising an amino acid sequence identical or substantially identical to LTSNLES (SEQ ID NO:31), and a light chain variable region CDR3 comprising an amino acid sequence identical or substantially identical to QQNNEDPFT (SEQ ID NO:32).~~
2. ~~The binding agent of claim 1, wherein:~~
 - (a) ~~the heavy chain variable region comprises the heavy chain variable region CDR1 comprising the amino acid sequence GFTFSSYGMS (SEQ ID NO:27), the heavy chain variable region CDR2 comprising the amino acid sequence TISGGGSYTNYPDSVKG (SEQ ID NO:28), and the heavy chain variable region CDR3 comprising the amino acid sequence REWRMTLYAMDY (SEQ ID NO:29), and~~
 - (b) ~~the light chain variable region comprises the light chain variable region CDR1 comprising the amino acid sequence RASESVDSYGNFSMH (SEQ ID NO:30), the light chain variable region CDR2 comprising the amino acid sequence LTSNLES (SEQ ID NO:31), and the light chain variable region CDR3 comprising the amino acid sequence QQNNEDPFT (SEQ ID NO:32).~~
3. ~~The binding agent according to any one of claims 1-2, wherein the heavy chain variable region has at least 80% sequence identity to SEQ ID NO:111.~~
4. ~~The binding agent according to any one of claims 1-3, wherein the light chain variable region has least 80% sequence identity to SEQ ID NO:112.~~
5. ~~The binding agent of any one of claims 1-4, wherein:~~

the heavy chain variable region has at least 80% sequence identity to SEQ ID NO:111 and the light chain variable region has at least 80% sequence identity to SEQ ID NO:112.

6. ~~The binding agent of any one of claims 1-5, wherein the heavy chain variable region has at least 90% sequence identity to SEQ ID NO:111.~~
7. ~~The binding agent of any one of claims 1-6, wherein the light chain variable region has at least 90% sequence identity to SEQ ID NO:112.~~
8. ~~The binding agent of any one of claims 1-7, wherein:
the heavy chain variable region has at least 90% sequence identity to SEQ ID NO:111
and the light chain variable region has at least 90% sequence identity to SEQ ID NO:112.~~
9. ~~The binding agent any one of claims 1-8, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:111.~~
10. ~~The binding agent of any one of claims 1-9, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO:112.~~
11. ~~The binding agent of any one of claims 1-10, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:111 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:112.~~
12. ~~The binding agent of claim 1, wherein:
(a) ~~the heavy chain variable region comprises the heavy chain variable region CDR1 comprising the amino acid sequence GFTFSSYGMS (SEQ ID NO:27), the heavy chain variable region CDR2 comprises the amino acid sequence TISGGGSYTNYPDSVKG (SEQ ID NO:28), and the heavy chain variable region CDR3 comprises the amino acid sequence REWRYTLYAMDY (SEQ ID NO:105), and~~
(b) ~~the light chain variable region comprises the light chain variable region CDR1 comprises the amino acid sequence RASESVESYGSSFMH (SEQ ID NO:106), the light chain variable region CDR2 comprises the amino acid sequence LTSNLES (SEQ ID NO:31), and the light chain variable region CDR3 comprises the amino acid sequence QQNNEDPFT (SEQ ID NO:32).~~~~
13. ~~The binding agent according to claim 1 or 12, wherein the heavy chain variable region has at least 80% sequence identity to SEQ ID NO:123.~~

- ~~14. The binding agent according to any one of claims 1, 12 and 13, wherein a light chain variable region has at least 80% sequence identity to SEQ ID NO:124.~~
 - ~~15. The binding agent of any one of claims 1 and 12-14, wherein:
the heavy chain variable region has at least 80% sequence identity to SEQ ID NO:123
and the light chain variable region has at least 80% sequence identity to SEQ ID NO:124.~~
 - ~~16. The binding agent of any one of claims 1 and 11-15, wherein a heavy chain variable region has at least 90% sequence identity to SEQ ID NO:123.~~
 - ~~17. The binding agent of any one of claims 1 and 11-16, wherein the light chain variable region has at least 90% sequence identity to SEQ ID NO:124.~~
 - ~~18. The binding agent of any one of claims 1 and 11-17, wherein:
the heavy chain variable region has at least 90% sequence identity to SEQ ID NO:123
and the light chain variable region has at least 90% sequence identity to SEQ ID NO:124.~~
 - ~~19. The binding agent any one of claims 1 and 11-18, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:123.~~
 - ~~20. The binding agent of any one of claims 1 and 11-19, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO:124.~~
 - ~~21. The binding agent of any one of claims 1 and 11-20, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:123 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:124.~~
-
- ~~221. A binding agent that specifically binds human immunoglobulin-like transcript 3 (ILT3), comprising:ILT3, wherein the binding agent comprises
(i) a heavy chain variable region (VH) comprising a heavy chain variable region CDR1 (VH-CDR1), a heavy chain variable region CDR2 (VH-CDR2), and a heavy chain variable region CDR3 (VH-CDR3) from the amino acid sequence of SEQ ID NO:111 and a light chain variable region comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO:112.~~
 - ~~23. A binding agent that specifically binds human ILT3, wherein the binding agent comprises a heavy chain variable region comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from of the amino acid sequence of SEQ ID NO:123, and a light chain variable region (VL) comprising a light chain variable region CDR1 (-VL-~~

CDR1), a light chain variable region CDR2 (VL-CDR2), and a light chain variable region CDR3 (VL-CDR3) ~~from a light chain variable region having of~~ the amino acid sequence set forth in SEQ ID NO:124;

(ii) a heavy chain variable region (VH) comprising a heavy chain variable region CDR1 (VH-CDR1), a heavy chain variable region CDR2 (VH-CDR2), and a heavy chain variable region CDR3 (VH-CDR3) of the amino acid sequence set forth in SEQ ID NO: 117; and a light chain variable region (VL) comprising a light chain variable region CDR1 (VL-CDR1), a light chain variable region CDR2 (VL-CDR2), and a light chain variable region CDR3 (VL-CDR3) of the amino acid sequence set forth in SEQ ID NO: 118;

(iii) a heavy chain variable region (VH) comprising a heavy chain variable region CDR1 (VH-CDR1), a heavy chain variable region CDR2 (VH-CDR2), and a heavy chain variable region CDR3 (VH-CDR3) of the amino acid sequence set forth in SEQ ID NO: 111; and a light chain variable region (VL) comprising a light chain variable region CDR1 (VL-CDR1), a light chain variable region CDR2 (VL-CDR2), and a light chain variable region CDR3 (VL-CDR3) of the amino acid sequence set forth in SEQ ID NO: 112;

(iv) a heavy chain variable region (VH) comprising a heavy chain variable region CDR1 (VH-CDR1), a heavy chain variable region CDR2 (VH-CDR2), and a heavy chain variable region CDR3 (VH-CDR3) of the amino acid sequence set forth in SEQ ID NO: 109; and a light chain variable region (VL) comprising a light chain variable region CDR1 (VL-CDR1), a light chain variable region CDR2 (VL-CDR2), and a light chain variable region CDR3 (VL-CDR3) of the amino acid sequence set forth in SEQ ID NO: 110;

(v) a heavy chain variable region (VH) comprising a heavy chain variable region CDR1 (VH-CDR1), a heavy chain variable region CDR2 (VH-CDR2), and a heavy chain variable region CDR3 (VH-CDR3) of the amino acid sequence set forth in SEQ ID NO: 113; and a light chain variable region (VL) comprising a light chain variable region CDR1 (VL-CDR1), a light chain variable region CDR2 (VL-CDR2), and a light chain variable region CDR3 (VL-CDR3) of the amino acid sequence set forth in SEQ ID NO: 114;

(vi) a heavy chain variable region (VH) comprising a heavy chain variable region CDR1 (VH-CDR1), a heavy chain variable region CDR2 (VH-CDR2), and a heavy chain variable region CDR3 (VH-CDR3) of the amino acid sequence set forth in SEQ ID NO: 115; and a light chain variable region (VL) comprising a light chain variable region CDR1 (VL-CDR1), a light chain variable region CDR2 (VL-CDR2), and a light chain variable region CDR3 (VL-CDR3) of the amino acid sequence set forth in SEQ ID NO: 116;

(vii) a heavy chain variable region (VH) comprising a heavy chain variable region CDR1 (VH-CDR1), a heavy chain variable region CDR2 (VH-CDR2), and a heavy chain variable region CDR3 (VH-CDR3) of the amino acid sequence set forth in SEQ

ID NO: 119; and a light chain variable region (VL) comprising a light chain variable region CDR1 (VL-CDR1), a light chain variable region CDR2 (VL-CDR2), and a light chain variable region CDR3 (VL-CDR3) of the amino acid sequence set forth in SEQ ID NO: 120; or

(viii) a heavy chain variable region (VH) comprising a heavy chain variable region CDR1 (VH-CDR1), a heavy chain variable region CDR2 (VH-CDR2), and a heavy chain variable region CDR3 (VH-CDR3) of the amino acid sequence set forth in SEQ ID NO: 121; and a light chain variable region (VL) comprising a light chain variable region CDR1 (VL-CDR1), a light chain variable region CDR2 (VL-CDR2), and a light chain variable region CDR3 (VL-CDR3) of the amino acid sequence set forth in SEQ ID NO: 122.

2. The binding agent of claim 1, wherein (a) the VH comprises the VH-CDR1, the VH-CDR2, the VH-CDR3 of the amino acid sequence set forth in SEQ ID NO: 123; and (b) the VL comprises the VL-CDR1, the VL-CDR2, and the VL-CDR3 of the amino acid sequence set forth in SEQ ID NO: 124.

3. The binding agent of claim 2, wherein:

(i) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 36, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 28, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 105, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 106, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 31, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 32;

(ii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 27, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 28, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 105, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 106, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 31, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 32;

(iii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 33, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 34, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 105, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 106, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 31, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 32;

(iv) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 27, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 35, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 105, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 106, the VL-

CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 31, and the VL-
CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 32; or
(v) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 37, the
VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 38, the VH-
CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 107, the VL-
CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 108, the VL-
CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 41, and the VL-
CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 42.

4. The binding agent of claim 2 or 3, wherein the VH comprises the amino acid
sequence set forth in SEQ ID NO: 123, and the VL comprises the amino acid
sequence set forth in SEQ ID NO: 124.

~~24. The binding agent of any one of claims 1-23, which is an antibody.~~

~~25. The binding agent of any one of claims 1-24, which is a monoclonal antibody.~~

~~26. The binding agent of any one of claims 1-25, which is a chimeric antibody.~~

~~27. The binding agent of any one of claims 1-25, which is a humanized antibody.~~

~~28. The binding agent of any one of claims 1-27, which is a bispecific antibody or a
multispecific antibody.~~

~~29. The binding agent of any one of claims 1-23, which is an antibody fragment
comprising at least one antigen-binding site.~~

~~30. The binding agent of claim 29, wherein the antibody fragment is a Fab, Fab', F(ab')₂,
Fv, scFv, (scFv)₂, single chain antibody, dual variable region antibody, diabody, or
nanobody.~~

~~31. The binding agent of any one of claims 1-28, which is an IgG1 antibody, optionally a
human IgG1 antibody, and further optionally a human IgG1 antibody having reduced
or no effector function.~~

~~32. The binding agent of any one of claims 1-28, which is an IgG2 antibody, optionally a
human IgG2 antibody.~~

~~33. The binding agent of any one of claims 1-28, which is an IgG4 antibody, optionally a
human IgG4 antibody.~~

~~34. The binding agent of any one of claims 1-28 or 31-33, which comprises a kappa light chain constant region, optionally a human kappa light chain constant region.~~

~~35. The binding agent of any one of claims 1-28 or 31-33, which comprises a lambda light chain constant region, optionally a human lambda light chain constant region.~~

~~365. An antibody that specifically binds human ILT3~~The binding agent of any one of claims 2-4, which comprises comprising a heavy chain comprising the amino acid sequence of set forth in SEQ ID NO:126 and a light chain comprising the amino acid sequence of set forth in SEQ ID NO:128.

6. The binding agent of claim 1, wherein (a) the VH comprises the VH-CDR1, the VH-CDR2, the VH-CDR3 of the amino acid sequence set forth in SEQ ID NO: 117; and (b) the VL comprises the VL-CDR1, the VL-CDR2, and the VL-CDR3 of the amino acid sequence set forth in SEQ ID NO: 118.

~~37. A binding agent that specifically binds human immunoglobulin-like transcript 3 (ILT3), which comprises:~~

~~(a) a heavy chain variable region comprising a heavy chain variable region CDR1 comprising an amino acid sequence identical or substantially identical to GFSLTSGVH (SEQ ID NO:11), a heavy chain variable region CDR2 comprising an amino acid sequence identical or substantially identical to VIWPGGTINYNSALMS (SEQ ID NO:12), and a heavy chain variable region CDR3 comprising an amino acid sequence identical or substantially identical to DKYDGGWFAY (SEQ ID NO:13), and~~

~~(b) a light chain variable region comprising a light chain variable region CDR1 comprising an amino acid sequence identical or substantially identical to KASQNVRTAVA (SEQ ID NO:14), a light chain variable region CDR2 comprising an amino acid sequence identical or substantially identical to LASNRHT (SEQ ID NO:15), and a light chain variable region CDR3 comprising an amino acid sequence identical or substantially identical to LQHLNYPLT (SEQ ID NO:16).~~

~~38. The binding agent of claim 37, wherein the heavy chain variable region has at least 80% identity to SEQ ID NO:109 and the light chain variable region has at least 80% identity to SEQ ID NO:110.~~

39. ~~The binding agent of claim 38, wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:109 and the light chain variable region has the amino acid sequence SEQ ID NO:110.~~
40. ~~A binding agent that specifically binds ILT3, which comprises a heavy chain variable region comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO:109, and a light chain variable region comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO:110.~~
41. ~~A binding agent that specifically binds human immunoglobulin-like transcript 3 (ILT3), which comprises:~~
- (a) ~~a heavy chain variable region comprising a heavy chain variable region CDR1 comprising an amino acid sequence identical or substantially identical to GYTFTDYNMD (SEQ ID NO:43), a heavy chain variable region CDR2 comprising an amino acid sequence identical or substantially identical to YIYPNNGGTCYNQKFNS (SEQ ID NO:44), and a heavy chain variable region CDR3 comprising an amino acid sequence identical or substantially identical to SPYYDYVGSYAMDY (SEQ ID NO:45), and~~
- (b) ~~a light chain variable region comprising a light chain variable region CDR1 comprising an amino acid sequence identical or substantially identical to TASSSVSSSYLH (SEQ ID NO:46), a light chain variable region CDR2 comprising an amino acid sequence identical or substantially identical to STSNLAS (SEQ ID NO:47), and a light chain variable region CDR3 comprising an amino acid sequence identical or substantially identical to HQYHRSPRT (SEQ ID NO:48).~~
42. ~~The binding agent of claim 41, wherein the heavy chain variable region has at least 80% identity to SEQ ID NO:113 and the light chain variable region has at least 80% identity to SEQ ID NO:114.~~
43. ~~The binding agent of claim 42, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:113 and the light chain variable region comprises the amino acid sequence SEQ ID NO:114.~~
44. ~~A binding agent that specifically binds ILT3, which comprises a heavy chain variable region comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO:113 and a light variable region comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO:114.~~

45. ~~A binding agent that specifically binds human immunoglobulin-like transcript 3 (ILT3), which comprises:~~
- ~~(a) — a heavy chain variable region comprising a heavy chain variable region CDR1 comprising an amino acid sequence identical or substantially identical to GYTFTDYNMD (SEQ ID NO:43), a heavy chain variable region CDR2 comprising an amino acid sequence identical or substantially identical to YIYPSNGGTGYNQKFKS (SEQ ID NO:59), and a heavy chain variable region CDR3 comprising an amino acid sequence identical or substantially identical to VPYYDYLYYYAMDY (SEQ ID NO:60), and~~
 - ~~(b) — a light chain variable region comprising a light chain variable region CDR1 comprising an amino acid sequence identical or substantially identical to RASSSVSFMH (SEQ ID NO:61), a light chain variable region CDR2 comprising an amino acid sequence identical or substantially identical to ATSNLAS (SEQ ID NO:62), and a light chain variable region CDR3 comprising an amino acid sequence identical or substantially identical to QQWSTNPYMYT (SEQ ID NO:63).~~
46. ~~The binding agent of claim 45, wherein the heavy chain variable region has at least 80% identity to SEQ ID NO:115 and the light chain variable region has at least 80% identity to SEQ ID NO:116.~~
47. ~~The binding agent of claim 46, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:115 and the light chain variable region comprises the amino acid sequence SEQ ID NO:116.~~
48. ~~A binding agent that specifically binds human ILT3, which comprises a heavy chain variable region comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO:115 and a light chain variable region comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO:116.~~
497. The A-binding agent that specifically binds human immunoglobulin-like transcript 3 (ILT3), which comprises of claim 6, wherein:
- ~~(a) — a heavy chain variable region comprising a heavy chain variable region (i) the VH-CDR1 comprising comprises an the amino acid sequence set forth in SEQ ID NO: 80, identical or substantially identical to GFTFSDYGMH (SEQ ID NO:71), a heavy chain variable region the VH-CDR2 comprising an amino acid sequence identical or substantially identical to YIFSGSSTIYYADTVKG (comprises the amino acid sequence set forth in SEQ ID NO:72), and a heavy chain variable region the VH-CDR3 comprising comprises an the amino acid sequence identical or substantially identical to ADGRGAMDY (set forth in~~

SEQ ID NO:73), and the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 74, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 75, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 76;

- ~~(b) — (ii) a light chain variable region comprising a light chain variable region the~~
VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 71, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 72, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 73, the VL-CDR1 comprises the amino acid sequence set forth in
~~comprising an amino acid sequence identical or substantially identical to RASQDISKFLN (SEQ ID NO:74), a light chain variable region the VL-~~
CDR2 comprising comprises an the amino acid sequence identical or
~~substantially identical to YTSRLHS (set forth in SEQ ID NO:75), and a light~~
chain variable region the VL-CDR3 comprising comprises an the amino acid
~~sequence identical or substantially identical to QQGNTLPWT (set forth in~~
SEQ ID NO:76);
- (iii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 77, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 78, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 73, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 74, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 75, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 76;
- (iv) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 71, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 79, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 73, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 74, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 75, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 76; or
- (v) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 81, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 82, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 83, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 84, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 85, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 86.

50. — ~~The binding agent of claim 49, wherein the heavy chain variable region has at least 80% identity to SEQ ID NO:117 and the light chain variable region has at least 80% identity to SEQ ID NO:118, the heavy chain variable region has at least 80% identity~~

~~to SEQ ID NO:162 and the light chain variable region has at least 80% identity to SEQ ID NO:164, or the heavy chain variable region has at least 80% identity to SEQ ID NO:163 and the light chain variable region has at least 80% identity to SEQ ID NO:164.~~

518. ~~The binding agent of claim 50~~claim 6 or 7, wherein
- ~~(a) the heavy chain variable region VH comprises the amino acid sequence of set forth in SEQ ID NO:117, and the light chain variable region VL comprises the amino acid sequence set forth in SEQ ID NO:118;~~
 - ~~(b) the heavy chain variable region VH comprises the amino acid sequence of set forth in SEQ ID NO:162, and the light chain variable region VL comprises the amino acid sequence set forth in SEQ ID NO:164; or~~
 - ~~(c) the heavy chain variable region VH comprises the amino acid sequence of set forth in SEQ ID NO:163, and the light chain variable region VL comprises the amino acid sequence set forth in SEQ ID NO:164.~~
9. The binding agent of claim 1, wherein (a) the VH comprises the VH-CDR1, the VH-CDR2, the VH-CDR3 of the amino acid sequence set forth in SEQ ID NO: 111; and (b) the VL comprises the VL-CDR1, the VL-CDR2, and the VL-CDR3 of the amino acid sequence set forth in SEQ ID NO: 112.
10. The binding agent of claim 9, wherein:
- (i) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 36, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 28, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 29, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 30, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 31, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 32;
 - (ii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 27, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 28, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 29, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 30, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 31, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 32;
 - (iii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 33, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 34, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 29, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 30, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 31, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 32;

- (iv) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 27, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 35, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 29, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 30, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 31, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 32; or
- (v) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 37, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 38, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 39, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 40, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 41, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 42.

~~52. A binding agent that specifically binds human ILT3, which comprises a heavy chain variable region comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO: 117 and a light chain variable region comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO: 118.~~

11. The binding agent of claim 9 or 10, wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 111, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 112.

12. The binding agent of claim 1, wherein (a) the VH comprises the VH-CDR1, the VH-CDR2, the VH-CDR3 of the amino acid sequence set forth in SEQ ID NO: 109; and (b) the VL comprises the VL-CDR1, the VL-CDR2, and the VL-CDR3 of the amino acid sequence set forth in SEQ ID NO: 110.

13. The binding agent of claim 12, wherein:

(i) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 20, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 14, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 15, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16;

(ii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 11, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 14, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 15, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16;

- (iii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 17, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 18, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 14, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 15, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16;
- (iv) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 11, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 19, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 14, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 15, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16; or
- (v) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 21, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 22, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 23, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 24, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 25, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 26.
14. The binding agent of claim 12 or 13, wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 109, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 110.
15. The binding agent of claim 1, wherein (a) the VH comprises the VH-CDR1, the VH-CDR2, the VH-CDR3 of the amino acid sequence set forth in SEQ ID NO: 113; and (b) the VL comprises the VL-CDR1, the VL-CDR2, and the VL-CDR3 of the amino acid sequence set forth in SEQ ID NO: 114.
16. The binding agent of claim 15, wherein:
- (i) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 52, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 44, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 45, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 46, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 47, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 48;
- (ii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 43, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 44, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 45, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 46, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 47, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 48;

- (iii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 49, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 50, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 45, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 46, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 47, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 48;
- (iv) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 43, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 51, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 45, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 46, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 47, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 48; or
- (v) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 53, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 54, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 55, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 56, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 57, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 58.
17. The binding agent of claim 15 or 16, wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 113, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 114.
18. The binding agent of claim 1, wherein (a) the VH comprises the VH-CDR1, the VH-CDR2, the VH-CDR3 of the amino acid sequence set forth in SEQ ID NO: 115; and (b) the VL comprises the VL-CDR1, the VL-CDR2, and the VL-CDR3 of the amino acid sequence set forth in SEQ ID NO: 116.
19. The binding agent of claim 18, wherein:
- (i) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 52, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 59, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 60, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 61, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 62, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 63;
- (ii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 43, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 59, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 60, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 61, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 62, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 63;

- (iii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 49, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 64, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 60, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 61, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 62, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 63;
- (iv) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 43, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 65, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 60, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 61, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 62, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 63; or
- (v) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 53, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 66, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 67, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 68, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 69, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 70.

20. The binding agent of claim 18 or 19, wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 115, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 116.

- ~~53. A binding agent that specifically binds human immunoglobulin-like transcript 3 (ILT3), which comprises:~~
- ~~(a) a heavy chain variable region comprising a heavy chain variable region CDR1 comprising an amino acid sequence identical or substantially identical to GFTFSSYCMS (SEQ ID NO:27), a heavy chain variable region CDR2 comprising an amino acid sequence identical or substantially identical to TISSGGTYTFYPDSVKG (SEQ ID NO:87), and a heavy chain variable region CDR3 comprising an amino acid sequence identical or substantially identical to RCWLLHYYAMDY (SEQ ID NO:88), and~~
- ~~(b) a light chain variable region comprising a light chain variable region CDR1 comprising an amino acid sequence identical or substantially identical to RPSESVDSEFCNSFMH (SEQ ID NO:89), a light chain variable region CDR2 comprising an amino acid sequence identical or substantially identical to LSSKLES (SEQ ID NO:90), and a light chain variable region CDR3 comprising an amino acid sequence identical or substantially identical to QQHNEDPFT (SEQ ID NO:91).~~

54. ~~The binding agent of claim 53, wherein the heavy chain variable region has at least 80% identity to SEQ ID NO:119 and the light chain variable region has at least 80% identity to SEQ ID NO:120; the heavy chain variable region has at least 80% identity to SEQ ID NO:156 and the light chain variable region has at least 80% identity to SEQ ID NO:161; the heavy chain variable region has at least 80% identity to SEQ ID NO:157 and the light chain variable region has at least 80% identity to SEQ ID NO:161; the heavy chain variable region has at least 80% identity to SEQ ID NO:158 and the light chain variable region has at least 80% identity to SEQ ID NO:161; the heavy chain variable region has at least 80% identity to SEQ ID NO:159 and the light chain variable region has at least 80% identity to SEQ ID NO:161; or the heavy chain variable region has at least 80% identity to SEQ ID NO:160 and the light chain variable region has at least 80% identity to SEQ ID NO:161.~~

55. ~~The binding agent of claim 54, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:119 and the light chain variable region comprises the amino acid sequence SEQ ID NO:120; the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:156 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:161; the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:157 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:161; the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:158 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:161; the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:159 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:161; or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:160 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:161.~~

5621. ~~A binding agent that specifically binds human ILT3~~ The binding agent of claim 1,
wherein (a) the VH which comprises a heavy chain variable region comprising a the
VH-CDR1, at the VH-CDR2, and at the VH-CDR3 from of the amino acid sequence
offset forth in SEQ ID NO:119 ; and (b) the VL a light chain variable region
comprising a comprises the VL-CDR1, at the VL-CDR2, and at the VL-CDR3 from of
the amino acid sequence offset forth in SEQ ID NO:120.

22. The binding agent of claim 21, wherein:

(i) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 36, the
VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 87, the VH-
CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 88, the VL-CDR1
comprises the amino acid sequence set forth in SEQ ID NO: 89, the VL-CDR2

comprises the amino acid sequence set forth in SEQ ID NO: 90, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 91;

(ii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 27, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 87, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 88, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 89, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 90, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 91;

(iii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 33, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 92, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 88, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 89, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 90, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 91;

(iv) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 27, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 93, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 88, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 89, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 90, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 91; or

(v) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 37, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 94, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 95, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 96, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 97, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 98.

23. The binding agent of claim 21 or 22, wherein:

(a) the VH comprises the amino acid sequence set forth in SEQ ID NO: 119, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 120;

(b) the VH comprises the amino acid sequence set forth in SEQ ID NO: 156, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 161;

(c) the VH comprises the amino acid sequence set forth in SEQ ID NO: 157, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 161;

(d) the VH comprises the amino acid sequence set forth in SEQ ID NO: 158, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 161;

(e) the VH comprises the amino acid sequence set forth in SEQ ID NO: 159, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 161; or

(f) the VH comprises the amino acid sequence set forth in SEQ ID NO: 160, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 161.

57. ~~A binding agent that specifically binds human immunoglobulin-like transcript 3 (ILT3), which comprises:~~
- ~~(a) a heavy chain variable region comprising a heavy chain variable region CDR1 comprising an amino acid sequence identical or substantially identical to GFTFSDYGMH (SEQ ID NO:71), a heavy chain variable region CDR2 comprising an amino acid sequence identical or substantially identical to YISTGIITVYYADTVKG (SEQ ID NO:99), and a heavy chain variable region CDR3 comprising an amino acid sequence identical or substantially identical to ADGRGAMDY (SEQ ID NO:73), and~~
 - ~~(b) a light chain variable region comprising a light chain variable region CDR1 comprising an amino acid sequence identical or substantially identical to RASQDISNFLN (SEQ ID NO:100), a light chain variable region CDR2 comprising an amino acid sequence identical or substantially identical to YTSRLHS (SEQ ID NO:75), and a light chain variable region CDR3 comprising an amino acid sequence identical or substantially identical to QQGNTLPWT (SEQ ID NO:76).~~
58. ~~The binding agent of claim 57, wherein the heavy chain variable region has at least 80% identity to SEQ ID NO:121 and the light chain variable region has at least 80% identity to SEQ ID NO:122.~~
59. ~~The binding agent of claim 58, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:121 and the light chain variable region comprises the amino acid sequence SEQ ID NO:122.~~
6024. ~~A~~The binding agent ~~that of claim 1, wherein (a) the VH specifically binds human~~ of claim 1, wherein (a) the VH specifically binds human ~~ILT3, which comprises a heavy chain variable region comprising a the VH-CDR1, at the VH-CDR2, and at the VH-CDR3 from of the amino acid sequence of set forth in~~ ILT3, which comprises a heavy chain variable region comprising a the VH-CDR1, at the VH-CDR2, and at the VH-CDR3 from of the amino acid sequence of set forth in ~~SEQ ID NO:121; and (b) and a light chain variable region comprising the VL~~ SEQ ID NO:121; and (b) and a light chain variable region comprising the VL ~~comprises at the VL-CDR1, at the VL-CDR2, and at the VL-CDR3 from of the amino acid sequence of set forth in~~ comprises at the VL-CDR1, at the VL-CDR2, and at the VL-CDR3 from of the amino acid sequence of set forth in ~~SEQ ID NO:122.~~ SEQ ID NO:122.
25. The binding agent of claim 24, wherein:
- (i) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 80, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 99, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 73, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 100, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 75, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 76;

- (ii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 71, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 99, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 73, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 100, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 75, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 76;
- (iii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 77, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 101, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 73, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 100, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 75, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 76;
- (iv) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 71, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 102, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 73, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 100, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 75, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 76; or
- (v) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 81, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 103, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 83, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 104, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 85, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 86.

26. The binding agent of claim 24 or 25, wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 121, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 122.

~~61~~27. The binding agent of ~~any one of claims 37-60~~ any one of claims 1-26, which wherein the binding agent is an antibody.

~~62~~28. The binding agent of ~~any one of claims 37-61~~ claim 27, which wherein the binding agent is a monoclonal antibody-

~~63.~~ The binding agent of any one of claims 37-62, which is, a chimeric antibody-, a recombinant antibody.

~~64.~~ The binding agent of any one of claims 37-62, which is a humanized antibody-.

~~65. The binding agent of any one of claims 37-64, which is a bispecific antibody or a multispecific antibody.~~

~~66. The binding agent of any one of claims 37-60, which is an antibody fragment comprising at least one antigen-binding site.~~

~~67. The binding agent of claim 66, wherein the antibody fragment is a Fab, Fab', F(ab')₂, Fv, scFv, (scFv)₂, single chain antibody, dual variable region antibody, diabody, or nanobody.~~

~~68~~29. The binding agent of ~~any one of claims 37-65~~ claim 27 or 28, ~~which~~wherein the binding agent is an IgG1 antibody, ~~optionally a human IgG1 antibody, and further optionally a human IgG1 antibody having reduced or no effector function.~~

~~69. The binding agent of any one of claims 37-65, which is, an IgG2 antibody, optionally a human IgG2 antibody.~~

~~70. The binding agent of any one of claims 37-65, which is, or an IgG4 antibody, optionally a human IgG4 antibody.~~

~~71~~30. The binding agent of any one of claims ~~37-65 or 68-70~~ 27-29, ~~which~~wherein the binding agent comprises a kappa light chain constant region, ~~optionally a human kappa light chain constant region.~~

~~72. The binding agent of any one of claims 37-65 or 68-70, which comprises, or a lambda light chain constant region, optionally a human lambda light chain constant region.~~

31. The binding agent of any one of claims 27-30, wherein the binding agent comprises a human IgG1 constant region and a human kappa light chain constant region.

32. The binding agent of claim 31, wherein the human IgG1 constant region comprises one or more mutations that reduce or eliminate effector functions.

33. The binding agent of any one of claims 1-26, wherein the binding agent is an antibody fragment comprising at least one antigen-binding site.

34. The binding agent of claim 33, wherein the antibody fragment is a Fab, a Fab', a F(ab')₂, Fv, an scFv, an (scFv)₂, a single chain antibody, a dual variable region antibody, a diabody, or a nanobody.

- ~~73. The binding agent or antibody of any one of claims 1-72, which binds the extracellular domain of human ILT3.~~
- ~~74. The binding agent or antibody of any one of claims 1-72, which binds the D2 domain or the junction of D1 domain and D2 domain of human ILT3.~~
- ~~75. The binding agent or antibody of any one of claims 1-74, which has one or more of the following properties:~~
- ~~(i) binds cyno ILT3;~~
 - ~~(ii) binds human and cyno ILT3;~~
 - ~~(iii) does not bind ILT2, ILT4, ILT5, and LILRB5;~~
 - ~~(iv) does not bind LILRA1, LILRA2, LILRA4, LILRA5, and LILRA6;~~
 - ~~(v) is an ILT3 antagonist;~~
 - ~~(vi) inhibits ILT3 activity;~~
 - ~~(vii) inhibits ILT3 signaling in cells that express ILT3;~~
 - ~~(viii) inhibits binding of ILT3 to APOE;~~
 - ~~(ix) inhibits binding of ILT3 to fibronectin;~~
 - ~~(x) inhibits binding of ILT3 to CNTFR;~~
 - ~~(xi) inhibits ILT3 induced suppression of myeloid cells;~~
 - ~~(xii) inhibits ILT3 induced suppression of myeloid cell activity;~~
 - ~~(xiii) restores FcR activation in myeloid cells that express ILT3; and~~
 - ~~(xiv) restores chemokine production in myeloid cells that express ILT3.~~

~~7635. The binding agent of or antibody of any one any one of claims 1-75 1-34, wherein the binding agent is attached to a half-life extending moiety.~~

~~36. An isolated nucleic acid encoding the binding agent of any one of claims 1-35.~~

~~37. An expression vector comprising the nucleic acid of claim 36.~~

~~38. An isolated cell comprising the nucleic acid of claim 36 or the expression vector of claim 37.~~

~~77. An antibody that competes with the binding agent of any one of claims 1-76 for binding to human ILT3.~~

~~78. A pharmaceutical composition that comprises the binding agent or antibody of any one of claims 1-77 and a pharmaceutically acceptable carrier.~~

~~79. A pharmaceutical composition that comprises the antibody of claim 36 and a pharmaceutically acceptable carrier.~~

~~80. An isolated polynucleotide or polynucleotides encoding the binding agent of any one of claims 1-76.~~

~~81. An isolated polynucleotide or polynucleotides encoding the antibody of claim 36.~~

~~82. A vector or vectors comprising the polynucleotide or polynucleotides of claim 80 or claim 81.~~

~~83. An isolated cell comprising the polynucleotides of claim 80 or claim 81.~~

~~84. An isolated cell comprising the vector or vectors of claim 82.~~

~~85~~39. An isolated cell producing the binding agent of any one of claims ~~1-76~~1-35.

40. A pharmaceutical composition comprising (a) the binding agent of any one of claims 1-35; and (b) a pharmaceutically acceptable carrier.

41. A method of making a binding agent that specifically binds human ILT3, the method comprising:

(a) culturing the isolated cell of claim 38 under conditions that result in the expression of the binding agent, and

(b) isolating the binding agent;

optionally wherein the method further comprises formulating the binding agent as a sterile pharmaceutical composition.

~~86. An antibody that specifically binds human immunoglobulin-like transcript 3 (ILT3), wherein the antibody comprises:~~

~~—— (a) —— a heavy chain variable region comprising a heavy chain variable region CDR1 comprising an amino acid sequence identical to GFTFSSYGMS (SEQ ID NO:27), a heavy chain variable region CDR2 comprising an amino acid sequence identical to TISGGGSYTNYPDSVKG (SEQ ID NO:28), and a heavy chain variable region CDR3 comprising an amino acid sequence identical to REWRMTLYAMDY (SEQ ID NO:29) except with 1 amino acid substitution, optionally wherein the substitution is of the methionine at position 5 of SEQ ID NO:29; and~~

~~—— (b) —— a light chain variable region comprising a light chain variable region CDR1 comprising an amino acid sequence identical or substantially identical to RASESVDSYGNFSMH (SEQ ID NO:30) except with 1 or 2 amino acid substitutions, optionally wherein the substitutions are of the aspartic acid at position 7 and/or the asparagine at position 11 of SEQ ID NO:30, a light chain variable region CDR2 comprising an amino acid sequence identical to LTSNLES (SEQ ID NO:31),~~

and a light chain variable region CDR3 comprising an amino acid sequence identical to QQNNEDPFT (SEQ ID NO:32).

8742. A method of disrupting, inhibiting, or blocking the binding of ILT3 to fibronectin or fibronectin-induced ILT3 activity in a mixture of cells, the method comprising contacting the cells with the binding agent ~~or antibody~~ of any one of claims 1-7735.

~~88. A method of disrupting, inhibiting, or blocking fibronectin-induced ILT3 activity in a mixture of cells, comprising contacting the cells with the binding agent or antibody of any one of claims 1-77.~~

8943. A method of disrupting, inhibiting, or blocking ILT3-induced suppression of myeloid cells or ILT3-induced suppression of myeloid cell activity, the method comprising contacting the myeloid cells with the binding agent ~~or antibody~~ of any one of claims 1-771-35.

~~90. A method of disrupting, inhibiting, or blocking ILT3 induced suppression of myeloid cell activity, comprising contacting the myeloid cells with the binding agent or antibody of any one of claims 1-77.~~

9144. The method of claim 9043, which

- (i) restores FcR activity in the myeloid cells that express ILT3;
- (ii) restores chemokine production by the myeloid cells that express ILT3; and/or
- (iii) restores immune cell (*e.g.*, T-cell) proliferation and/or activity.

~~92. A method of disrupting, inhibiting, or blocking the binding of ILT3 to fibronectin in a subject, comprising administering to the subject an effective amount of the binding agent or antibody of any one of claims 1-77.~~

~~93. A method of disrupting, inhibiting, or blocking fibronectin-induced ILT3 activity in a subject, comprising administering to the subject an effective amount of the binding agent or antibody of any one of claims 1-77.~~

~~94. A method of disrupting, inhibiting, or blocking ILT3 induced suppression of myeloid cells in a subject, comprising administering to the subject an effective amount of the binding agent or antibody of any one of claims 1-77.~~

95. ~~A method of disrupting, inhibiting, or blocking ILT3-induced suppression of myeloid cell activity in a subject, comprising administering to the subject an effective amount of the binding agent or antibody of any one of claims 1-77.~~

96. ~~The method of claim 95, which:~~

- ~~(i) — restores FcR activity in the myeloid cells that express ILT3, and/or~~
- ~~(ii) — restores chemokine/cytokine production in the myeloid cells that express ILT3.~~

9745. Use of the binding agent of any one of claims 1-35 or the pharmaceutical composition of claim 39 in the manufacture of a medicament for~~A method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of~~ wherein the binding agent or antibody of any one of claims 1-35 or the pharmaceutical composition of claim 39 is to be administered to the subject.

9846. ~~The method~~use of claim 9745, wherein

- ~~(a) the cancer is pancreatic cancer, breast cancer, lung cancer, head and neck cancer, colorectal cancer, prostate cancer, skin cancer, melanoma, stomach cancer, gastric cancer, intestinal cancer, ovarian cancer, cervical cancer, uterine cancer, endometrial cancer, urinary bladder cancer, brain cancer, esophageal cancer, liver cancer, kidney cancer, sarcoma or testicular cancer;~~

99. ~~The method of claim 97, wherein (b) the cancer is a hematologic cancer;~~ or

100. ~~The method of claim 97, wherein (c) the cancer is myelogenous leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia, or myelodysplastic syndrome.~~

101. ~~A method of inhibiting tumor growth in a subject, the method comprising administering to the subject a therapeutically effective amount of the binding agent or antibody of any one of claims 1-77.~~

102. ~~A method of increasing or enhancing an immune response to a tumor or tumor cells in a subject, the method comprising administering to the subject a therapeutically effective amount of the binding agent or antibody of any one of claims 1-77.~~

103. ~~A method of activating or enhancing a persistent or long term immune response to a tumor or tumor cells in a subject, the method comprising administering to the subject a therapeutically effective amount of the binding agent or antibody of any one of claims 1-77.~~

- ~~104. A method of inhibiting tumor relapse or tumor regrowth in a subject, the method comprising administering to the subject a therapeutically effective amount of the binding agent or antibody of any one of claims 1-77.~~
- ~~105. A method of inducing a persistent or long-term immunity that inhibits tumor relapse or tumor regrowth in a subject, the method comprising administering to the subject a therapeutically effective amount of the binding agent or antibody of any one of claims 1-77.~~
- ~~106. The method of any one of claims 101-105, wherein the tumor is a pancreatic tumor, a breast tumor, a lung tumor, a head and neck tumor, a colorectal tumor, a prostate tumor, a skin tumor, a melanoma tumor, a stomach tumor, a gastric tumor, an intestinal tumor, an ovarian tumor, a cervical tumor, an uterine tumor, an endometrial tumor, a bladder tumor, a brain tumor, an esophageal tumor, a liver tumor, a kidney tumor, a sarcoma or a testicular tumor.~~
- ~~107. A method of activating myeloid cells in the tumor microenvironment in a subject with a tumor, the method comprising administering to the subject a therapeutically effective amount of the binding agent or antibody of any one of claims 1-77.~~
- ~~108. The method of claim 107, wherein the myeloid cells are primary dendritic cells or tolerogenic dendritic cells.~~
- ~~109. The method of claim 107, wherein the myeloid cells are monocytes or macrophages.~~
- ~~110. A method of reactivating tolerogenic dendritic cells in a subject, the method comprising administering to the subject a therapeutically effective amount of the binding agent or antibody of any one of claims 1-77.~~
- ~~111. The method of claim 110, wherein the tolerogenic dendritic cells are found in a tumor microenvironment.~~
- ~~112. The method of any one of claims 92-111, use of claim 45 or 46, wherein the binding agent or antibody is to be administered as part of a combination therapy, optionally wherein the combination therapy comprises an anti-PD-1 antibody.~~
- ~~113. The method of claim 112, wherein the combination therapy comprises at least one additional therapeutic agent.~~
- ~~114. The method of any one of claims 92-113, wherein the subject is a human.~~

~~11548.~~ ~~Use of the~~ The binding agent or antibody of any one of claims 1-77 ~~35 or the~~
pharmaceutical composition of claim 39 for use in ~~for~~ treatment of cancer.

49. The binding agent or the pharmaceutical composition of claim 48, wherein:

(a) the cancer is pancreatic cancer, breast cancer, lung cancer, head and neck cancer, colorectal cancer, prostate cancer, skin cancer, melanoma, stomach cancer, gastric cancer, intestinal cancer, ovarian cancer, cervical cancer, uterine cancer, endometrial cancer, urinary bladder cancer, brain cancer, esophageal cancer, liver cancer, kidney cancer, sarcoma or testicular cancer;

(b) the cancer is a hematologic cancer; or

(c) the cancer is myelogenous leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia, or myelodysplastic syndrome.

50. The binding agent or the pharmaceutical composition of claim 48 or 49, wherein the binding agent is to be administered as part of a combination therapy; optionally wherein the combination therapy comprises an anti-PD-1 antibody.

~~116.— Use of the binding agent or antibody of any one of claims 1-77 in the manufacture of a medicament for treatment of cancer.~~

~~117.— A method of making the binding agent or antibody of any one of claims 1-77, the method comprising:~~

~~(a) — culturing the cell of any one of claims 83-86, and~~

~~(b) — isolating the binding agent or antibody.~~

~~118.— The method of claim 117, further comprising purifying the binding agent or antibody.~~

~~119.— The method of claim 117 or claim 118, further comprising formulating the binding agent or antibody as a pharmaceutical composition.~~

~~12051.~~ An antibody that binds human ILT3 and inhibits binding of human ILT3 to fibronectin, optionally wherein the antibody has one or more of the following properties:

(i) the antibody also binds cyno ILT3;

(ii) the antibody does not bind, or only weakly binds (relative to ILT3), ILT2, ILT4, ILT5, and LILRB5;

(iii) the antibody does not bind, or only weakly binds (relative to ILT3), LILRA1, LILRA2, LILRA4, LILRA5, and LILRA6;

(iv) the antibody is an ILT3 antagonist;

(v) the antibody inhibits ILT3 activity;

- (vi) the antibody inhibits ILT3 signaling in cells that express ILT3;
- (vii) the antibody inhibits binding of ILT3 to APOE;
- (viii) the antibody inhibits binding of ILT3 to CNTFR;
- (ix) the antibody inhibits ILT3-induced suppression of myeloid cells;
- (x) the antibody inhibits ILT3-induced suppression of myeloid cell activity;
- (xi) the antibody restores FcR activation in myeloid cells that express ILT3; and
- (xii) the antibody restores chemokine production in myeloid cells that express ILT3.

~~121~~52. The antibody of claim ~~120~~51, which has a K_D for human ILT3 of 1 μ M to 1 pM as assessed by Biacore.

~~122~~53. The antibody of claim ~~120~~51 or 52, which comprises a human IgG1 constant region and a human kappa light chain constant region; optionally

~~123~~. ~~The antibody of claim 122, wherein the human IgG1 constant region comprises one or more mutations that reduce or eliminate effector functions.~~

~~124~~54. A pharmaceutical composition comprising the antibody of any one of claims ~~120-123~~51-53, and a pharmaceutically acceptable carrier.

55. Use of the binding agent of any one of claims 51-53 or the pharmaceutical composition of claim 54 in the manufacture of a medicament for treating cancer in a subject, the binding agent of any one of claims 51-53 or the pharmaceutical composition of claim 54 is to be administered to the subject

~~125~~56. ~~A method of treating cancer in a human subject, the method comprising administering to the subject a therapeutically effective amount of the antibody of any one of claims 120-123 or the pharmaceutical composition of claim 124, optionally,~~
The use of claim 55, wherein the cancer is: a cancer that expresses high levels of fibronectin, a cancer expressing ILT3, pancreatic cancer, breast cancer, lung cancer, head and neck cancer, colorectal cancer, prostate cancer, skin cancer, melanoma, stomach cancer, gastric cancer, intestinal cancer, ovarian cancer, cervical cancer, uterine cancer, endometrial cancer, urinary bladder cancer, brain cancer, esophageal cancer, liver cancer, kidney cancer, sarcoma or testicular cancer, a hematologic cancer, myelogenous leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia, or myelodysplastic syndrome.

~~126. A pharmaceutical composition comprising~~
~~— (a) means for inhibiting the interaction between human ILT3 and fibronectin; and~~
~~— (b) a pharmaceutically acceptable carrier.~~

~~127. The pharmaceutical composition of claim 126, wherein the means for inhibiting the interaction between human ILT3 and fibronectin is an anti-human ILT3 antibody.~~

~~128. The pharmaceutical composition of claim 127, wherein the antibody comprises the VH-CDR1, VH-CDR2, and VH-CDR3 of a heavy chain variable region and the VL-CDR1, VL-CDR2, and VL-CDR3 of a light chain variable region, wherein the heavy chain variable region and the light chain variable region comprises the amino acids sequences respectively in:~~

- ~~—— (i) SEQ ID NOs.:123 and 124;~~
- ~~—— (ii) SEQ ID NOs.:156 and 161~~
- ~~—— (iii) SEQ ID NOs.:157 and 161;~~
- ~~—— (iv) SEQ ID NOs.: 158 and 161;~~
- ~~—— (v) SEQ ID NOs.:159 and 161;~~
- ~~—— (vi) SEQ ID NOs.:160 and 161;~~
- ~~—— (vii) SEQ ID NOs.:162 and 164; or~~
- ~~—— (vii) SEQ ID NOs.:163 and 164.~~

~~129. The pharmaceutical composition of claim 128, wherein the antibody comprises the heavy chain variable region and the light chain variable region comprising the amino acids sequences, respectively, in:~~

- ~~—— (i) SEQ ID NOs.:123 and 124;~~
- ~~—— (ii) SEQ ID NOs.:156 and 161~~
- ~~—— (iii) SEQ ID NOs.:157 and 161;~~
- ~~—— (iv) SEQ ID NOs.: 158 and 161;~~
- ~~—— (v) SEQ ID NOs.:159 and 161;~~
- ~~—— (vi) SEQ ID NOs.:160 and 161;~~
- ~~—— (vii) SEQ ID NOs.:162 and 164; or~~
- ~~—— (vii) SEQ ID NOs.:163 and 164.~~

~~130~~57. A combination comprising (i) a binding agent ~~or antibody~~ of any one of claims ~~1-77~~1-35 ~~or the antibody of any one of claims 120-123~~51-53, and (ii) an anti-PD-1 antibody.

~~131. A combination comprising means for inhibiting the interaction between human ILT3 and fibronectin and an anti PD-1 antibody.~~